GREENLAND MINES LTD Deferred Offering Costs
GREENLAND MINES LTD (GRML) had Deferred Offering Costs of $8.37 million as of 2024-03-31, per its 10-Q filed 2024-05-23.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2024-05-23
- 2024-03-31: Deferred Offering Costs $8.37M.
- 2023-12-31: Deferred Offering Costs $8.37M.
- 2023-09-30: Deferred Offering Costs $8.37M.
- 2023-06-30: Deferred Offering Costs $8.37M.
| Period end | Deferred Offering Costs |
|---|---|
| 2024-03-31 | $8.37M 10-Q · filed 2024-05-23 |
| 2023-12-31 | $8.37M 10-K · filed 2024-04-17 |
| 2023-09-30 | $8.37M 10-Q · filed 2023-11-17 |
| 2023-06-30 | $8.37M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $8.37M 10-Q · filed 2023-05-24 |
| 2022-12-31 | $8.37M 10-K/A · filed 2023-10-18 |
| 2022-09-30 | $8.37M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $8.37M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $221.06K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |